September 15, 2023
Completed a Novel Object Recognition memory experiment which demonstrated our shRNA compound improved memory in rats 103%.
Having proven efficacy with anxiety in mice in April, this new memory breakthrough represents a second indication for our shRNA compound which could potentially help millions of patients with Alzheimer’s and Mild Cognitive Impairment.
Completed in vitro validation testing for shRNA compound in human cortical neurons.
- 26% decrease in 5-HT2A receptor population.
- 34% decrease in 5-HT2A mRNA levels.
- 35% decrease in neuron firing rate
June 20, 2023
The Cognigenics science team has released a significant new paper on PNAS Nexus: Genetic modulation of the HTR2A gene reduces anxiety-related behavior in mice. In this study, we demonstrate the feasibility of noninvasive, intranasal delivery of adeno-associated virus serotype 9 (AAV9) vectors containing CRISPR/Cas9 cargo within the CNS resulting in modification of the HTR2A receptor gene.
April 27, 2023
New data: Light/dark test: Mice treated with our RNA compound displayed significantly less anxious behaviour than controls. Since our lead asset, RCA-101, will use an RNA design, this experiment represents a key milestone for the company. Earlier experiments have used DNA editing which has fewer variables than RNA and is therefore more straightforward. This new experiment validates the RNA design, which is protected by forthcoming patents.
January 7, 2023
Cognigenics, Inc. Annual Report
September 20, 2022
A light dark (LD) test was performed to evaluate the relative anxiety status of mice. The results were highly significant pointing to the effectiveness of the Cognigenics CRISPR application in reducing anxiety in mice. If given a choice between a large brightly compartment versus a small dark compartment, mice spontaneously prefer the dark. This test measured how long mice spent in light and dark areas of a box. The less anxious a mouse is, the more prone they are to venture into the light area. Mice receiving the Cognigenics CRISPR spent 36% more time in the light area.
June 13, 2022
Cognigenics, Inc. received an investment of $950,000 from Fifth Set Ventures and Lionheart Ventures. This funding will support the company’s preclinical research program for developing next-generation mental health technology.
December 15, 2021
An early prototype of the company’s RNA therapy for anxiety and depression performed similarly to brand name pharmaceutical drugs in animal laboratory tests without any evidence of side effects.
September 1, 2021
In a second series of combined behavioral, neuroanatomical, and genomic studies in an animal model of anxiety and depression, the Cognigenics scientific team successfully demonstrated their platform technology delivers a uniquely-designed CRISPR cargo to cellular targets in the brain associated specifically with anxiety, depression, and emotional memory. The genomic modification of the specific cell targets occurs in animal treatments which were previously targeted in Cognigenics’ first experiment, which significantly ameliorated stress and anxiety. A third series of multimodal genetic neuroengineering experiments is underway to determine the time-dose interactive effects of the treatments using longer time courses and varying doses.
June 10, 2021
The company’s first behavioral experiment demonstrated statistically-significant anxiety reduction in mice receiving our gene therapy versus a control group.
April 15, 2021
Reagents manufactured for mice behavioral experiment.
March 24, 2021
Design completed for mice anxiety behavior experiment.
February 11, 2021
Cognigenics, Inc. received additional angel funding.
January 6, 2021
Decision made to test wild-type mice anxiety reduction with intranasal CRISPR delivery.
November 27, 2020
Transgenic mice founder generation born.
October 16, 2020
Transgenic embryonic stem cells grown.
September 5, 2020
CRISPR reagents formulated for transgenic experiment.
August 21, 2020
Design competed for CRISPR-Cas9 reagents for research experiments.
July 15, 2020
The company received initial funding from early angel investors.